Beam Therapeutics (NASDAQ:BEAM – Get Rating) and Denali Therapeutics (NASDAQ:DNLI – Get Rating) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Insider & Institutional Ownership 68.8% of Beam Therapeutics shares […]
Beam Therapeutics (NASDAQ:BEAM – Get Rating) and Orchard Therapeutics (NASDAQ:ORTX – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends. Valuation & Earnings This table compares Beam Therapeutics and Orchard […]
Magenta Therapeutics (NASDAQ:MGTA – Get Rating) had its price target reduced by investment analysts at The Goldman Sachs Group from $3.00 to $2.00 in a report issued on Tuesday, Stock Target Advisor reports. The firm presently has a “buy” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential upside of […]
Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) – Analysts at B. Riley reduced their Q2 2022 EPS estimates for Magenta Therapeutics in a research report issued to clients and investors on Tuesday, May 17th. B. Riley analyst K. Patel now anticipates that the company will post earnings per share of ($0.41) for the quarter, down […]
Rare Disease Drug Developers Face Bear Market in April globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.